The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial launch generated significant returns, the expiration of its exclusive rights opened the door to off-brand alternatives, https://thegreatbookmark.com/story21654897/the-copyright-and-the-pharmaceutical-industry-a-risky-bet